galactomannan and Inflammation

Guar gum-derived galactomannan (GGGM) has been widely used in the food industry for a long time and its adverse impacts have been scarcely reported. Galactomannan is considered to have a structure similar to the surface components of certain pathogens, and the present study was thus conducted to investigate if oral administration of GGGM could cause physiological effects that were hypothesized to be related to intestinal inflammatory responses. The results showed that oral administration of GGGM resulted in compromises on growth performance, an increase of the relative weight of spleen and epididymal fat, and an elevation of the α1-acid glycoprotein content in both serum and livers of mice. With regard to energy metabolism-related indices, the activities of intestinal lactic dehydrogenase and succinic dehydrogenase were all increased by the GGGM treatment in both in vivo and in vitro experiments, the latter of which also showed an elevation in the consumption of reducing sugar by intestinal epithelial cells along with a reduced viability of these cells in response to the GGGM treatment. Notably, the GGGM treatment triggered intestinal inflammatory responses that were evidenced by the increased expression of intestinal inflammatory cytokines such as TNF-α and IL-6 both in vivo and in vitro, which were at least partially responsible for the increased energy expenditure in the intestine and the retardation of growth. The results of this study could expand our knowledge of GGGM administration and provide integrated insights into the consumption of GGGM-containing foods.

Topics: Animals; Disease Models, Animal; Energy Metabolism; Galactans; Galactose; Inflammation; Intestines; Male; Mannans; Mice; Plant Gums

In the present study, a glucogalactomanan polysaccharide isolated from Agaricus bisporus named as TJ3 was investigated its immunomodulatory effects and molecular mechanisms in RAW 264.7 cells. Functional analysis showed TJ3 could inhibit the proliferation of RAW 264.7 cells in a certain concentration range. Moreover, TJ3 treatment increased the expression of inducible nitric oxide synthase (iNOS), which was responsible for increasing nitric oxide (NO) production. TJ3 also increased the expression of cyclooxygenase-2 (COX-2) and the mRNA levels of interleukin 1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) and COX-2 in RAW 264.7 cells. In addition, further elucidation of molecular mechanisms showed that ERK/MAPK and IκB/NFκB pathways were activated by TJ3 treatment via increased phosphorylation levels of ERK1/2 and IκB-α, respectively. These findings indicated that TJ3 had a huge promising immunostimulatory activity and its induced immune responses probably through stimulating the ERK/MAPK and IκB/NFκB pathways. Our results demonstrate that TJ3 may be used as a potent immune modulator.

Topics: Agaricus; Animals; Biomarkers; Cell Survival; Cyclooxygenase 2; Extracellular Signal-Regulated MAP Kinases; Fungal Polysaccharides; Galactose; I-kappa B Proteins; Immunomodulation; Inflammation; Macrophages; Mannans; Mice; NF-kappa B; Nitric Oxide; Prostaglandin-Endoperoxide Synthases; RAW 264.7 Cells; Signal Transduction

Topics: Animals; Apoptosis; Caesalpinia; Carcinoma, Hepatocellular; Cell Proliferation; Galactose; Humans; Inflammation; Liver; Liver Neoplasms; Male; Mannans; Plant Extracts; Rats; Rats, Wistar; Tumor Cells, Cultured

We describe a novel wound dressing (HR006) with two components: a lyophilized matrix of the galactomannan from locust bean gum (LBG) and an antioxidant hydration solution (AHsol) containing curcumin and N-acetyl-L-cysteine (NAC). Physico-structural analyses of the LBG matrix revealed homogeneous interconnected pores with high absorbing capacity showing excellent properties for moist wound care (MWC). In an in vitro oxidative stress fibroblast injury model, the AHsol showed relevant protective effects reducing intracellular reactive oxygen species (ROS) production, rescuing cell viability, and regulating expression of inflammation-related genes (COX-2, TNF-α, IL-1α, IL-1β). The new dressing showed good biocompatibility profile as demonstrated by cytotoxicity, hemocompatibility, and skin irritation tests. Moreover, in an in vivo skin wound model in pigs, this dressing enhanced the production of healthy and organized granulation tissue and re-epithelization. In summary, HR006 exhibits significant antioxidant activity, good biocompatibility, and excellent repair capabilities improving tissue remodeling and the healing of wounds.

Topics: Acetylcysteine; Animals; Antioxidants; Bandages; Curcumin; Cytokines; Fibroblasts; Galactans; Galactose; Humans; Inflammation; Irritants; Mannans; Materials Testing; Oxidative Stress; Plant Gums; Reactive Oxygen Species; Sus scrofa; Wound Healing

We show that galactomannan, a polysaccharide consisting of a mannose backbone with galactose side groups present on the cell wall of several fungi, induces a reprogramming of the inflammatory response in human macrophages through dectin-1 receptor. The nuclear factor kappa-light-chain-enhancer of activated B cells 2 (NFκB2)/p100 was overexpressed after galactomannan challenge. Knocking down NFκB2/p100 using small interfering RNA (siRNA) indicated that NFκB2/p100 expression is a crucial factor in the progression of the galactomannan-induced refractoriness. The data presented in this study could be used as a modulator of inflammatory response in clinical situations where refractory state is required.

Topics: Blotting, Western; Cell Proliferation; Cells, Cultured; Flow Cytometry; Galactose; Humans; Inflammation; Lipopolysaccharides; Macrophages; Mannans; NF-kappa B p52 Subunit; RNA, Small Interfering